Articles

In the September issue, we published an editorial entitled “I Am a Nurse Practitioner, NOT a Mid-Level Provider,” in which author Alison Moriarty Daley provided an argument against this phrase. We asked our online reading community what they think about “mid-level provider.”

  • 17% accepted mid-level provider as an accurate term
  • 50%agreed with Ms Daley that it is an insult
  • 33% didn’t think it mattered since nobody knows what the term means
Read More ›

A recent study shows postmenopausal women with new-onset breast tenderness after beginning estrogen and progestin therapy may have an increased risk of breast cancer compared to women who don’t suffer breast tenderness. Researchers from UCLA’s Jonsson Comprehensive Cancer Center conducted the study, which appears in the early online edition of the peer-reviewed journal Breast Cancer Research and Treatment.

Read More ›

SAN FRANCISCO—A number of interventions can help reduce breast cancer among women at high risk, but uptake is sluggish, and there can be confusion about which agent to prescribe to a given patient. Seema Khan, MD, professor of surgery at Northwestern University Feinberg School of Medicine, Chicago, addressed the topic of pharmacologic risk reduction at the 2011 Breast Cancer Symposium.

Read More ›

Although there is no straightforward answer to this question, the current recommended daily allowances for adults—600 IU for children and adults, and 800 IU for those older than 70 years— are probably too low.1,2 To provide a little background, vitamin D should be considered a prohormone rather than a vitamin (a substance humans need in small amounts and usually cannot synthesize).3 Animals convert 7-hydrocholesterol to calciferol (D3) in the dermis via a photochemical reaction with ultraviolet B (UVB) sunlight. Read More ›


CHICAGO—Screening all patients for hepatitis B surface antigen (HBsAg) before initiating chemotherapy for lymphoma is associated with improved clinical outcomes and is economically favorable, according to an analysis presented by researchers at the University of Toronto and St Michael’s Hospital, Toronto, Ontario, at the annual meeting of the American Society of Clinical Oncology.

Read More ›

CHICAGO—Targeted drugs are very effective in patients with a well-specified molecular target. Examples include imatinib in patients with chronic myelog enous leukemia and trastuzumab in HER2-positive breast cancer. Evidence, however, has shown only modest improvements in outcomes when targeted agents are given to “unselected patients,” that is, those lacking a tumor characteristic (or mutation) that is specifically addressed by a given drug. Read More ›


The National Women’s Hall of Fame recently inducted Loretta C. Ford, RN, EdD, PNP, FAAN, FAANP, along with 10 other American women who have made valuable and enduring contributions to our nation. These women were formally inducted on September 30 and October 1, 2011, in Seneca Falls, New York, the birthplace of the American Women’s Rights Movement.

Read More ›

WASHINGTON, DC—Psychosocial stress may play a role in the etiology of breast cancer aggressiveness, particularly among minority populations, according to study results. In a cross-sectional study, greater levels of fear, anxiety, or isolation were found to be associated with more aggressive breast cancer; however, no clear driver for the association is yet identified.

Read More ›

The following articles are based on presentations at the Fourth American Association for Cancer Research Conference on The Science of
Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved held September 18-21, 2011, in Washington, DC


WASHINGTON, DC—The overall incidence of breast cancer is generally higher among white women than black women. The incidence of a second breast cancer in the opposite breast, however, is higher among black women, according to new data.

Read More ›

After a long series of treatments for stage IV ovarian cancer, I finished my last chemotherapy session in March 2010. About 2 months later, I realized I missed the camaraderie and friendships I had developed during the hours of waiting for the chemotherapy to be administered. I looked for a support group and soon joined the Scripps GYN Support Group that meets twice monthly. By that point, I had started sharing the story of my journey with ovarian cancer, finding that others were helped when they heard it.

Read More ›

Page 318 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: